Good morning. My name is Dave, and I will be your operator today. At this time, I would like to welcome you to Imunon's First Quarter 20254 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. Following the speakers prepared remarks; there will be a question-and-answer session. [Operator Instructions] I would now like to turn the call over to Peter Vozzo of ICR Healthcare, Investor Relations representative for Imunon. Please go ahead.

Thank you, Dave. Good morning, everyone and welcome to Emunan's first quarter 2025 financial results and business update conference call. During today's call, management will be making forward-looking statements regarding Imunon's expectations and projections about future events. In general, forward-looking statements can be identified by words, such as expects, anticipates, believes or other similar expressions. These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic filings with the Securities and Exchange Commission. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. I also caution that, the content of this conference call is accurate only as of the date of the live broadcast, May 12, 2025. Imunon undertakes no obligation to revise or update comments made during this call, except as required by law. With that said, I would like to turn the call over to Dr. Stacy Lindborg, President and Chief Executive Officer. Stacey?

Thank you, Peter, and good morning, everyone. Joining me on this call is Dr. Douglas Faller, Imunon's Chief Medical Officer; and David Gaiero, our Interim Chief Financial Officer who will review our financial results for the first quarter of 2025. Michael Tardugno, the Executive Chairman of our Board; and Dr. Khursheed Anwer, our Chief Scientific Officer are also both on the line and will be available for Q&A. I want to start by saying that we may be close for the first time to unlocking the power of interleukin-12 to effectively treat cancer in one of the worst forms ovarian cancer. Our work in developing treatments for ovarian cancer, a disease that continues to challenge scientists and clinicians, and researchers underscores our commitment to addressing unmet medical needs and driving long-term value. I'm amazed at the number of discussions I've had since joining Imunon in both personal and professional settings where people shared impact from ovarian cancer at a close and personal level. Its devastation has no limits in taking the lives of women, young and old in their prime. We continue to make significant strides towards our goal of transforming the treatment landscape for women diagnosed with advanced ovarian cancer. To that end, I'm pleased to report that we have initiated the first clinical site in our Phase III pivotal study of Imunon-001. If the results from our highly successful Phase II study are replicated in Phase III, patients and doctors may potentially have a meaningful life extending therapy that recruits and empowers body's immune system to effectively target this disease. Our Phase III study known as OVATION 3 is being recognized by the medical community as a critical step towards the goal of delivering a new frontline treatment for women with limited options and unmet, urgent medical needs.…

Thank you, Stacy. This is clearly a very exciting time for IMMUNON. In addition to the presentation of the results from our Ovation 2 trial at an oral session of ASCO in a few weeks and the simultaneous journal publication which Stacy mentioned we've also been invited to present new translational data from the OVATION 2 trial at the International ESMO Gynecological Conference in June. The new data that we will present demonstrate that IMMUNON 001 technology performs exactly as it was designed delivering highly potent IL-12 gene therapy directly to the site of the tumor while keeping systemic exposure to IL-12 extremely low. This is the proprietary biochemical basis for both Imunon's anti-cancer activity and just as important its safety. We initiated the first clinical site in our registrational OVATION 3 trial last week with the second site to be initiated in two days. More site initiations are planned in the coming weeks. It is gratifying to me as a clinician and informative to note that these leading hospitals and internationally known principal investigators were also major participants in ovation too. Their enthusiasm actually their insistence for joining Ovation 3 speaks to their belief in the safety and potential benefit of IMNN-001 in the women they care for. They want to join with us in this crucial step towards bringing IMNN-001 forward as a novel and innovative therapeutic in ovarian cancer. Our highly experienced clinical development team is excited to have initiated the OVATION 3 trial and is eagerly planning the expansion of the trial over the next six months. I'll now turn the call back to Stacey.

Thanks, Douglas. As we look towards financing our Phase 3 clinical trial, our goal is twofold. One is to ensure that we have done the best possible job for all stakeholders including our shareholders. And two, to raise capital in an amount that allows us to achieve our product development goals. And dilution is top of mind as we consider these options. Moreover and importantly, we have taken steps to conserve cash and align our critical needs with available capital on hand, while adding to the balance sheet through optimal opportunities. We're actively working on value-added financing and partnerships which will help secure a cash runway that supports our clinical timelines and long-term strategic objectives. Focusing on both technologies, TheraPlas and PlaCCine, we are having discussions with potential partners that have significant investment in oncology as well as vaccine development some of these under CDA. We are also exploring geographic partnerships and ways to accelerate development of IMNN-001 in other parts of the world. And finally, we intend to leverage the data from the proof of concept trial, using our novel PlaCCine vaccine technology to sell or license that technology. Our PlaCCine technology offers several advantages and strong advantages over other vaccine platforms such as exceptional stability being viable for one year at 4 degree centigrade refrigerated temperatures and one month at 37 degree Celsius. The platform also has the ability for rapid adaptation to new pathogens or variants, longer lasting protection or durability. Meaning it could be less frequent booster shots and cost-effective manufacturing. We shared insights from the PlaCCine proof of concept trial and the preclinical trials in this month, this last month April 2025 at both the AACR annual meeting and at the World Vaccine Congress and are following up with companies in the vaccine space. We are actively working on value-added financing and partnerships, which will help secure a cash runway. We will provide updates when we're able and our goal is to cover OVATION 3 trial cost through corporate partnerships and equity. I'd now like to turn the call over to Dave Gaiero to review our financial results for the first quarter. Dave?

Thank you, Stacy. Details of Imunon's first quarter 2025 financial results are included in the press release we issued this morning and in our Form 10-Q, which we filed before the market opened this morning. As of March 31, 2025, Imunon had $2.9 million in cash and cash equivalents. We remain focused on securing near-term financing to strengthen the company's financial condition and advance OVATION 3. Research and development costs were $2.2 million for the first quarter of 2025, compared with $3.3 million for the same period in 2024. The decrease was due primarily to lower costs associated with the Phase 1 proof of concept PlaCCine DNA vaccine trial and the development of PlaCCine DNA vaccine technology platform. General and administrative expenses were $2 million for the first quarter of 2025 compared to $1.7 million for the same period in 2024. The increase was primarily due to higher employee related expenses. Net loss for the first quarter of 2025 was $4.1 million or $0.28 per share compared to a net loss of $4.9 million or $0.52 per share for the same period in 2024. With that financial review, I turned the call back to Stacy.

Thank you, Dave. With that, I'd like to open the call to your questions. Operator?

We will now begin the question-and-answer session. [Operator Instructions] Our first question comes from Emily Bodnar with H.C. Wainwright. Please go ahead.

Hello, Emily.

Hi. Thanks for taking the questions. Hello, and congrats on the progress. I guess first one I'll ask about the ASCO presentation, so congrats, obviously on getting an Oral Presentation. Is there anything new in terms of like subgroup analysis or any new data analysis that we should be expecting at the ASCO presentation and will you potentially have the median OS for the HRD positive patients by then?

So we are by nature of ASCO's embargo, Emily, I know you'll understand that not able to talk about the content of the presentation. They're very careful with what is shared in advance. We will be sharing new information and that I think is really quite central to being accepted as an oral presentation although I think the full body of evidence that we've been discussing merits a view at this at this level and at a platform like ASCO. So we're incredibly excited. For the presentation, I look forward to hearing Dr. Thaker's perspective on the data.

Okay. Makes sense. And then maybe just follow-up on the Phase III design. How many sites are you expecting to have in total for the trial for that, I guess, first half portion that you were discussing and then are you having OS as a dual primary endpoint for HRD positive and the ITT population or how are you kind of splitting up the statistical plan? Thanks.

I'll have Doug, when you take a step in.

Sure. The analysis for the Phase III has always been predicated on analyzing the HRD population first. This is the population in which we think from probation to data including data that will be presented at ASCO in which we have the highest effect in terms of activity. And so the population that would be read out first whether we proceeded with the entire HRD and HRP or whether we focused on HRD alone, as Stacy mentioned, the readout does not change. There are two interim analyses and a final analysis if needed all based on HRD events. You asked the question.

A number of sites.

A number of sites. We are projecting about 45 sites at this point.

Yes. Emily just to recap, so the overall survival of the primary is not dual and it is consistent for all populations as the primary.

Got it. Okay. Thank you.

The last question comes from James Molloy with Alliance Global Partners. Please go ahead.

Hello. This is Laura Suriel on for Jim Malloy. Thank you for taking my questions and congrats on the progress. So for OVATION 3 what's the current status that you have on like the inventory and the manufacturing capabilities for this trial especially with the 250 to 500 page enrollment plan that you have set up?

Yes. Great question and I'll take the opportunity just to reiterate that for this trial, we have pulled the manufacturing of the core active pharmaceutical ingredients in-house and we are prepared and are monitoring various enrollment plans and ensuring that we have and will have -- continue to have product available. So we have had product that has passed all of the release specifications and has been ready to sit for weeks now and are well prepared for the weeks and months ahead.

Got it. Thank you. And then also the clinical trial that you have in collaboration with the Breakthrough Cancer Foundation, what's the current status of this trial here? And are you still on track to have preliminary results announced later on this year?

You just had a call with the PIs. Can you just give some insight from that?

We have a meeting with the principal investigators every two weeks. And the last one was a couple of days ago on Friday. We've initiated another site, University of Oklahoma and very excited about that. Johns Hopkins has managed to re-staff its clinical research group. And so they're excited about starting to screen patients. We are expecting to have data at the end of this year, yes.

All right. Thank you for the answers. Thanks for taking the questions.

Thank you.

This concludes our question-and-answer session of the call. I now want to turn the call back over to Imunon's President and CEO for including remarks, Dr. Lindborg.

Thank you. I want to reiterate our near-term focus, which is on securing funds to strengthen the company's financial condition and advancing our Phase III trial and in the process, advancing IMNN-001. We expect to have an update on this front by the end of this quarter. And as referenced earlier, our goal is to cover the OVATION 2 trial cost, and we want to and will be seeking corporate partnering and equity financing. We expect this will be an iterative process driven by catalysts to further investor confidence and follow-on financings. And as our work in providing a new treatment option for women with ovarian cancer progresses and as the population's exposure to potential pandemics increases, we remain very excited about reporting data from ongoing clinical studies in the months ahead. We look forward to keeping you appraised of our progress and thanks again for joining us today and for your interest in Imunon.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.